The plasminogen-MMP system is more activated in the scar than in viable myocardium 3:months post-MI in the rat

Journal of Molecular and Cellular Cardiology

Volumn 38, Issue 1, 2005, Pages 193-204

  Gaertner, Roger ^a   Jacob, Marie Paule ^a   Prunier, Fabrice ^a   Angles Cano, Eduardo ^a   Mercadier, Jean Jacques ^a   Michel, Jean Baptiste ^a  

^a INSERM   (France)

Author keywords

Cardiac remodeling; Experimental heart failure; MMP; Plasminogen plasmin system

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HYPOTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; BODY WEIGHT; CICATRIX; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

ANIMALIA; RATTUS NORVEGICUS;

EID: 11144314783     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.10.017     Document Type: Article

References (40)

1. J.P. Cleutjens, W.M. Blankesteijn, M.J. Daemen, and J.F. Smits The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions Cardiovasc. Res. 44 1999 232 241
2. K. Schwartz, Y. Lecarpentier, J.L. Martin, A.M. Lompre, J.J. Mercadier, and B. Swynghedauw Myosin isoenzymic distribution correlates with speed of myocardial contraction J. Mol. Cell. Cardiol. 13 1981 1071 1075
3. J.B. Michel, A.L. Lattion, J.L. Salzmann, M.L. Cerol, M. Philippe, and J.P. Camilleri Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction Circ. Res. 62 1988 641 650
4. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210
5. H.R. Lijnen Plasmin and matrix metalloproteinases in vascular remodeling Thromb Haemost 86 2001 324 333
6. C. Boixel, V. Fontaine, C. Rucker-Martin, P. Milliez, L. Louedec, and J.B. Michel Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat J Am Coll Cardiol 42 2003 336 344
7. R. Gaertner, F. Prunier, M. Philippe, L. Louedec, J.J. Mercadier, and J.B. Michel Scar and pulmonary expression and shedding of ACE in rat myocardial infarction Am J Physiol Heart Circ Physiol 283 2002 H156 H164
8. F. Prunier, R. Gaertner, L. Louedec, J.B. Michel, J.J. Mercadier, and B. Escoubet Doppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats Am J Physiol Heart Circ Physiol 283 2002 H346 H352
9. N. Schiller, P. Shah, and M. Crawford Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimentional Echocardiograms J Am Soc Echocard 2 1989 358 367
10. C. Badier-Commander, T. Verbeuren, C. Lebard, J.B. Michel, and M.P. Jacob Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation J. Pathol. 192 2000 105 112
11. V. Fleury, and E. Angles-Cano Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines Biochemistry 30 1991 7630 7638
12. V. Fontaine, M.P. Jacob, X. Houard, P. Rossignol, D. Plissonnier, and E. Angles-Cano Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms Am J Pathol 161 2002 1701 1710
13. P. Chomcynski, and N. Sacchi Single-step method of RNA isolation by acid guanidium thiocynate-phenol-chloroform extraction Ann Biochem 162 1987 156 159
14. E. Angles-Cano, B. Boutiere, D. Arnoux, C. Masson, G. Contant, and P. Benchimol Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay Thromb. Haemost. 58 1987 843 849
15. J.B. Michel, A. Nicolletti, and J.F. Arnal Left ventricular remodelling following experimental myocardial infarction Eur. Heart J. 16 Suppl I 1995 49 57
16. S. Litwin, S. Katz, J. Morgan, and P. Douglas Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat Circulation 89 1994 345 354
17. R. Bailey, J. Lehman, S. Gubin, and T. Musch Non-invasive assessment of ventricular damage in rats with myocardial infarction Cardiovasc. Res. 27 1993 851 855
18. I. Sjaastad, O. Sejersted, A. Ilebekk, and R. Bjonerheim Echocardiographic criteria for detection of postinfarction congestive heart failure in rats Appl Physiol 89 2000 1445 1454
19. M. Stromqvist, K.E. Karlsson, P. Bjorquist, J.O. Andersson, M. Bystrom, and L. Hansson Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography Biochim. Biophys. Acta 1295 1996 103 109
20. J.P. Cleutjens, J.C. Kandala, E. Guarda, R.V. Guntaka, and K.T. Weber Regulation of collagen degradation in the rat myocardium after infarction J. Mol. Cell. Cardiol. 27 1995 1281 1292
21. M.L. Coker, C.V. Thomas, M.J. Clair, J.W. Hendrick, R.S. Krombach, and Z.S. Galis Myocardial matrix metalloproteinase activity and abundance with congestive heart failure Am. J. Physiol. 274 1998 H1516 H1523
22. S.C. Tyagi, S.E. Campbell, H.K. Reddy, E. Tjahja, and D.J. Voelker Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts Mol. Cell. Biochem. 155 1996 13 21
23. F.G. Spinale, M.L. Coker, L.J. Heung, B.R. Bond, H.R. Gunasinghe, and T. Etoh A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
24. J.T. Peterson, H. Li, L. Dillon, and J.W. Bryant Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat Cardiovasc. Res. 46 2000 307 315
25. S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, and L. Moons Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure Nat. Med. 5 1999 1135 1142
26. L.E. Rohde, A. Ducharme, L.H. Arroyo, M. Aikawa, G.H. Sukhova, and A. Lopez-Anaya Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice Circulation 99 1999 3063 3070
27. M.L. Lindsey, J. Gannon, M. Aikawa, F.J. Schoen, E. Rabkin, and L. Lopresti-Morrow Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction Circulation 105 2002 753 758
28. S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, and T. Kubota Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction Am J Physiol Heart Circ Physiol 285 2003 H1229 H1235
29. H. Li, H. Simon, T.M. Bocan, and J.T. Peterson MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition Cardiovasc. Res. 46 2000 298 306
30. J.F. Woessner Jr. Matrilysin Methods Enzymol. 248 1995 485 495
31. A.M. Henney, P.R. Wakeley, M.J. Davies, K. Foster, R. Hembry, and G. Murphy Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization Proc. Natl. Acad. Sci. USA 88 1991 8154 8818
32. Y. Sun, J.Q. Zhang, J. Zhang, and S. Lamparter Cardiac remodeling by fibrous tissue after infarction in rats J. Lab. Clin. Med. 135 2000 316 323
33. O.P. Rahkonen, I.M. Koskivirta, S.M. Oksjoki, E. Jokinen, and E.I. Vuorio Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA Biochim Biophys Acta 1577 2002 45 52
34. E. Creemers, J. Cleutjens, J. Smits, S. Heymans, L. Moons, and D. Collen Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction Am. J. Pathol. 156 2000 1865 1873
35. L. Zhang, D. Seiffert, B.J. Fowler, G.R. Jenkins, T.C. Thinnes, and D.J. Loskutoff Plasminogen has a broad extrahepatic distribution Thromb Haemost 87 2002 493 501
36. A. Bonnefoy, and C. Legrand Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase Thromb. Res. 98 2000 323 332
37. Z.L. Chen, and S. Strickland Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin Cell 91 1997 917 925
38. K. Macfelda, T.W. Weiss, C. Kaun, J.M. Breuss, G. Zorn, and U. Oberndorfer Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes J Mol Cell Cardiol 34 2002 1681 1691
39. K. Takeshita, M. Hayashi, S. Iino, T. Kondo, Y. Inden, and M. Iwase Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction Am J Pathol 164 2004 449 456
40. H.P. Kohler, and P.J. Grant Plasminogen-activator inhibitor type 1 and coronary artery disease N. Engl. J. Med. 342 2000 1792 1801